Ignite Creation Date:
2025-12-24 @ 10:44 PM
Ignite Modification Date:
2026-03-06 @ 1:22 PM
Study NCT ID:
NCT01158235
Status:
COMPLETED
Last Update Posted:
2011-06-08
First Post:
2010-07-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)
Sponsor:
Lytix Biopharma AS
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
C10-109-02
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Wenche Marie Olsen, Director of Development, Infectious Diseases
Old Organization:
Lytix Biopharma AS